Healthcare Business Report: Mylan’ Glycemic Med WINS FDA Okay, Teva Launches GENERIC

Pain Therapeutics (NASDAQ:PTIE) shares are initiated with a Buy at C.K. Cooper. The company intends to stay ahead of potentially good news on Remoxy, which is its extended release capsules of oxycodone that are being developed with Pfizer Inc. (NYSE:PFE). The med was rejected by the FDA in June, but the analyst thinks that shares will move up once Pfizer explains its plans for a resubmission.

Don’t Miss: Medtronic First Quarter Earnings Sneak Peek.

Mylan Inc. (NASDAQ:MYL) wins final FDA approval for its Pioglitazone Tablets which are generic versions of Takeda Pharmaceutical’s Actos Tablets and Actoplus Met Tablets, along with a virtual patent for 180 days. The medicine is indicated as a supplement to diet and exercise in the improvement of glycemic control among adults suffering from type 2 diabetes mellitus.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) reports its intro of generic ACTOplus met in the United States. The med is marketed by Takeda Pharmaceuticals and is used as a supplement to diet and exercise to improve blood sugar control in adults with type 2 diabetes. ACTOplus met saw annual domestic sales of around $413 million through June.

Don’t Miss:  Google Finds This Friend For Wallet.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.